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ABSTRACT 
 
DELETION OF FSTL3 AND/OR FST ISOFORMS FST303 AND 315 RESULTS IN 
HEPATIC STEATOSIS 
SEPTEMBER 2010 
NATHAN UNGERLEIDER, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Alan Schneyer 
 
 
TGFβ ligands, activin and myostatin have been shown to stimulate insulin production 
and secretion. Antagonists, Follistatin (FST) and Follistatin like 3 (FSTL3) were partially 
and fully ablated, respectively, creating hyperinsulinemic mice with fatty liver. Much 
research has surfaced on the connection between hepatic steatosis and hepatic insulin 
resistance. We present two different models, each with a different mechanism behind 
the development of fatty liver. FST288-only mice have increased synthesis of mRNA 
and proteins responsible for hepatic triglyceride (TG) uptake, while our double mutants 
have increased synthesis of mRNA and proteins responsible for TG synthesis.  This 
alteration was likely independent of hepatic insulin resistance as livers from both mouse 
lines were insulin sensitive. Experiments conducted in this study to realize the causal 
factor of hepatic steatosis can be performed on adipose and muscle tissues in the future 
to better characterize the phenotype. 
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CHAPTER 1 
 
INTRODUCTION 
 
 Type II Diabetes Mellitus is a common disease affecting an increased proportion 
of the population each year. Twenty three million people in the United States have been 
diagnosed with the disease with another 57 million considered to be pre-diabetic1. 
Insulin, produced by beta cells of the pancreas, regulates a variety of metabolic systems 
including glucose and fat uptake and storage and protein synthesis. Cells become 
insulin resistant in many different ways. From a macroscopic level, target cells become 
less responsive to insulin over time, requiring more insulin for the same effect. The 
mechanisms by which this occurs will be described in more detail below. The organs 
relevant to this study which are known to become insulin resistant are muscle, adipose, 
and liver.  
For many years, the term insulin resistance has been used to describe impaired 
glucose control with respect to the entire body. However, in the early portion of this 
century tissue specific insulin receptor knockouts were generated. Comparing the 
phenotype of different tissue specific insulin receptor knockouts (Table 1), it became 
clear that different tissues can contribute uniquely to the diabetes syndrome2. A liver 
insulin receptor knockout (LIRKO) mouse exhibited extreme postprandial 
hyperglycemia, extreme hyperinsulinemia (20 fold higher serum insulin levels), β-cell 
hypertrophy, and decreased circulating free fatty acids and triglycerides3 . The muscle 
insulin receptor knockout (MIRKO) showed normal blood glucose and insulin levels4,  
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53% increase in epididymal fat pad weight, and a 38% increase in whole-body fat 
content5,6. They also have a 16% increase in circulating free fatty acids and a 43% 
increase in serum triglycerides3. The fat insulin receptor knockout (FIRKO) shows 
fasting insulin levels are decreased by 45%, decreased serum triglycerides, and 
sustained glucose tolerance and insulin sensitivity to an older age than control mice. 
This shows that liver insulin resistance has the most pathological effect, while adipose 
insulin resistance appears to ameliorate the diabetic phenotype.   
The insulin receptor models characterize the effects of a complete interruption in 
signaling. While this is helpful in determining the effect insulin resistance on each organ 
has on the entire body, it is not a perfect representation of type 2 diabetes. After 
observance of diabetic mice with impaired insulin stimulated gluconeogenesis but with 
enhanced insulin stimulated lipogenesis, Brown and Goldstein published a model of 
postreceptor insulin resistance7. The lipogenic pathway begins with the same insulin 
receptor and splits off the glucose regulatory pathway downstream, allowing for the 
possibility of different levels of response sensitivity. 
Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most common liver 
diseases in the world today8.  The relationship between insulin resistance, type 2 
diabetes mellitus (TIIDM), and Non-Alcoholic Fatty Liver Disease is a complex one. 
Most cases of NAFLD are strongly associated with hepatic insulin resistance9,10 and it 
affects around 20 million patients in the United States alone11.  Type 2 diabetics who 
undergo weight loss end up lowering their liver TGs and impoving their hepatic insulin 
sensitivity12. The accumulation of lipids in liver tissue causes hepatic steatosis, which 
3 
 
progresses into non alcoholic steatohepatitis (cirrhosis of liver tissue). The liver is a 
major regulator of lipid uptake and storage as well as cleavage and metabolism. NAFLD 
is a result of a disparity in the uptake + production versus the secretion + oxidation of 
free fatty acids and triglycerides. Hepatic lipid uptake can be linked to peripheral 
adipose tissue lipid secretion as well as postprandial lipid absorption.  De novo 
lipogenesis (the synthesis of lipids from glucose precursors), beta oxidation, and 
triglyceride secretion in the form of VLDLs take place in the hepatocytes themselves, 
and are regulated by insulin to some extent.  
Activin and myostatin appear to have important metabolic functions, but have 
been somewhat understudied for this role. Two known antagonists of activin and 
myostatin are follistatin (FST)13 and follistatin like protein 3 (FSTL3)14. A knockout of 
FST and FSTL3 allows for the enhanced activity of activin and myostatin. The complete 
FST knockout is not viable so the contribution of FST to energy homeostasis is 
impossible to discern from this model. FSTL3 knockout animals survive and are born in 
normal mendelian ratios and are thus useful for this application. An FSTL3 knockout 
mouse demonstrated an increase in pancreatic islet number and size, β-cell 
hyperplasia, decreased visceral fat mass, improved glucose tolerance, and enhanced 
insulin sensitivity15. Other then the hepatic steatosis, the phenotype appeared to be anti-
diabetic.  
Alternative splicing results in two different mRNAs produced from the fst gene, 
one of which undergoes post-translational processing resulting in a total of three FST 
isoforms, FST288, FST303, and FST31516. FST288 has the highest affinity for heparan 
sulfate proteoglycans and is therefore suggested to be a tissue-bound protein. FST303, 
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the intermediate isoform, is also found bound to tissue, but not as strongly17 and found 
primarily in gonadal fluids. FST315 is considered the circulating isoform due to its weak 
binding of heparin sulfate proteoglycans18. In order to study the effects of FST ablation, 
it was necessary to leave the FST 288 isoform intact, which is the apparent isoform 
required for development. FST288-only mice were created by altering the fst gene to 
delete alternative splicing19 Now with two different genetically modified mouse lines 
(FST288-only, FSTL3 KO), each one having a complementary antagonist rendered 
inactive, the next step was to mate these mice to create a double mutant mouse line 
(DM). The DM (FST303-/-, FST315-/-, FSTL3-/-), is as close as we can come to a 
complete ablation of the antagonists of myostatin and activin. The present study 
focuses on the comparison of these three genetically modified mice lines.  
Mice of each genotype and their wildtype littermates were analyzed over a 2 year 
period23. The unpublished data helped give direction to this liver study and is 
summarized in Table 1. Total fat composition in FST288-only and FSTL3 KO was 
similar to WT levels but DM mice displayed a 150% increase in percent body fat. All 
three genotypes had a 33% reduction in visceral fat pad mass. This could be due to an 
attenuated insulin response in their visceral fat since visceral adipose tissue is known to 
be more insulin resistant than subcutaneous fat20. Insulin inhibits lipolysis21, explaining 
how insulin resistant adipose tissue can diminish in size; more triglycerides will be 
cleaved and released in this state.  
Mice over 6 months of age showed no hyperglycemia with random and fasting 
glucose tests. Only DM had a significant (2-fold) increase in random serum insulin 
compared to either WT. During GTTs, DM mice were more glucose intolerant and 
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insulin resistant than single mutant FST288-only mice or WT littermates. FST288-only 
mice have normal GTT, ITT, and body fat percentages and do not appear diabetic 
based on these physiological tests. FSTL3 KOs appear to be particularly anti-diabetic. 
They are glucose tolerant, insulin sensitive, and have high serum insulin levels22. This 
could indicate that FSTL3 has a greater antagonistic activity than FST, with partial FST 
ablation producing only undetectable effects. Furthermore upon combination of the anti-
diabetic FSTL3 KO and normal FST288-only, the result is a diabetic mouse. Based on 
the physiologic study alone, the DM genotype appeared to be insulin resistant, while the 
other genotypes seemed to maintain their insulin sensitivity even with enhanced islet 
function. Because the liver has a direct role in the maintenance of metabolite 
homeostasis, a defect in the liver insulin response was expected.  
 
HEPATIC INSULIN RESISTANCE: GLUCOSE REGULATION 
 
Hepatic insulin resistance can have very serious diabetic implications. Following 
fasting, the liver is the major source of plasma glucose, and hepatic glucose output is 
tightly regulated by insulin23. A healthy liver responds to insulin signaling by reducing 
gluconeogenesis and glycogenolysis, and secondarily by increasing glucose storage via 
glycogenesis. In insulin resistant states, the liver will still secrete glucose postprandially. 
If β-cells are properly functioning, the excess circulating glucose will cause 
hyperinsulinemia. High insulin levels can downregulate their own signal response 
pathways as a form of negative feedback, resulting in insulin resistance. 
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Insulin acts on many different tissues and it is unlikely that every tissue develops 
resistance at the same rate. In addition, multiple forks in signal cascades can make it 
difficult to pinpoint which component of the pathway is responding irregularly. Insulin 
signal transduction begins with the circulating hormone binding to the extracellular α-
domains of the heterodimeric insulin receptor (IR). Once bound, the intermembranal β-
domains of the receptor exhibit tyrosine kinase activity24 and phosphorylate the insulin 
receptor substrate proteins (IRS1, IRS2, IRS3, IRS4). These eventually activate PI3 
kinase, which then phosphorylates AKT at the serine residues, activating this kinase. 
These are considered the main intermediate steps in the signal cascade and eventually 
produce the known insulin response. One way insulin inhibits gluconeogenesis is by 
repressing the transcription of phosphoenolpyruvate carboxykinase (PEPCK) 25 and 
glucose-6-phosphatase (G6Pase)26. PEPCK in its enzymatic form is responsible for the 
conversion of oxaloacetate into phosphoenolpyruvate, the rate limiting step in 
gluconeogenesis. G6Pase catalyzes the hydrolysis of glucose-6-phosphate into 
glucose27, a required final step in both gluconeogenesis and glycogenolysis. Hepatic 
glucokinase (GCK) is an important enzyme for glucose storage and its mRNA 
expression is known to be depressed in diabetic states and restored to normal with 
insulin treatment28. Glucokinase is responsible for the phosphorylation of glucose to 
glucose-6-phosphate, the opposite function of G6Pase. IRS1 and IRS2 are understood 
to be the two most relevant of the IRS isoforms. IRS1/IRS2 are downregulated in 
diabetic patients29 and insufficient levels of IRS1/IRS2 will impair insulin response at all 
downstream targets. To test for the sensitivity of insulin regulation at the transcriptional 
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level, we decided to quantify the mRNA levels of G6Pase, PEPCK, GCK, IRS1, and 
IRS2. 
Glycogenesis is the conversion of glucose into its more efficient storage form, 
glycogen. Glycogen is a large branched polymer of glucose molecules. Fatty acids pack 
more energy per unit mass than glycogen, but glycogen can be readily broken down 
into glucose in the presence or absence of oxygen. This makes it the best functioning 
buffer for glucose levels. One of the better known results of insulin signaling in the liver 
is the upregulation of the glycogenic pathway. In insulin resistant liver tissue, we would 
expect glycogen stores to be lower, so we examined glycogen stores in the liver.  
  
HEPATIC INSULIN RESISTANCE: LIPID REGULATION 
 
The relevant insulin response can be broken down into two pathways: Glucose 
regulation and lipid regulation. The convergence of these two pathways can explain the 
connection between insulin resistance and fatty liver. Insulin has a direct and indirect 
role in lipid regulation. Insulin directly activates components of the lipogenic pathway. 
Insulin also causes glucose uptake into cells, causing the preferential burning of 
glucose for energy, thus saving the fat. Lastly, in one published diabetic mouse model, 
there is evidence of a “sensitivity split” where the glucose response sensitivity 
diminishes and lipid response pathway remains sensitive to insulin30. This is a possible 
explanation for the DM mice which have drastically increased serum insulin levels. To 
examine the severe hepatic steatosis found in our mice, mRNA and protein expression 
studies were first performed on components of the lipogenic pathway.  The study 
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included determining mRNA levels of both PPARγ and SREBP1c, as well as protein 
levels of SREBP1. Sterol regulatory element binding protein 1c (SREBP1c) is an 
important lipogenic transcription factor known to promote the expression of many 
lipogenic enzymes. Insulin stimulates SREBP1c activity31 even in insulin resistant 
states32. PPARγ is a transcription factor that promotes the expression of many genes 
involved in fatty acid uptake33.  
Because lipids are hydrophobic, they need to be carried through the blood by 
hydrophilic molecules. Low density lipoproteins are composed of cholesterols, 
triglycerides, and protein. In humans, at least 75% of circulating LDL is taken up by the 
liver via LDLR34. When overexpressed in mice, liver LDL receptor causes total serum 
cholesterol levels to be reduced to less than 50%35. Overexpressed lipoprotein lipase 
(LPL) in the liver results in steatosis36. We hypothesized that the genes involved in lipid 
uptake and lipogenesis would be upregulated in the livers of all of our knockout mice. 
 
HEPATIC STEATOSIS 
 
Some studies suggest that circulating fatty acids due to peripheral insulin 
resistance is the cause of fatty liver37. Blood is supplied to the liver through the portal 
vein and through the hepatic artery. The hepatic artery brings in oxygenated blood, and 
the portal vein brings in deoxygenated blood with nutrients and hormones (including 
insulin) from the GI tract. The two blood supplies combine and enter the sinusoids, the 
capillaries of the liver. Blood flows through the sinusoids, and finally exits through the 
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central vein. The hepatic artery, portal vein, and bile ducts form the “hepatic triads”. The 
hepatic triads form the vertices of the hexagonal lobule, the structural unit of the liver.  
 
DIRECT EFFECT MEDIATED BY THE TGFΒ LIGANDS 
 
The TGFβ ligands likely to have the highest bioactivity in the absence of FST303, 
FST315, and FSTL3 are myostatin and activin. Homozygous myostatin knockout mice 
were glucose tolerant and protected against insulin resistance38. Myostatin is primarily 
expressed in muscle and adipose tissue. Activin A has been found to enhance glucose 
stimulated insulin secretion of rat and human islets in culture39, as well as increase β-
cell proliferation40. While Activin A inhibits hepatocyte proliferation41, myostatin has no 
known direct effects on the liver. To determine if myostatin and activin had direct 
metabolic altering effects on the liver, mRNA expression data was collected.  
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CHAPTER 2 
METHODS 
Histology 
Liver tissues were isolated from mice and fixed in 4% paraformaldehyde 
overnight. The tissues were then processed for paraffin embedding. 6 µm microtome 
sections were stained with PAS reagent (for glycogen) and counterstained with 
Hematoxylin. Adjacent sections were stained with Hematoxylin for structure 
determination. The localization of lipids were examined with H&E staining. 
Glycogen Extraction 
Glycogen extraction was performed as previously described42. Liver tissues were 
harvested and 100 mg were homogenized in 3mL of 10% perchloric acid. Homogenates 
were centrifuged at 2500 x g for 15 minutes. Supernatant was separated and 5 mL of 
100% EtOH was added to each sample. Samples were left in the freezer overnight and 
centrifuged the following day at 2000 x g. Supernatent was discarded and glycogen 
pellet was reconstituted in 5 mL of ddH20.  
Glycogen Quantification 
Glycogen was quantified as previously described22. Samples and standards 
(Glycogen powder from Sigma) were diluted appropriately. 1 mL of 5% phenol was 
added to 1 mL of diluted sample and vortexed. 5 mL of concentrated sulfuric acid was 
then added to each sample. Each sample was shaken vigorously and measured with a 
spectrophotometer at 490 nm. 
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RT and QPCR 
Total RNA was extracted from flash frozen liver tissues with TRIzol (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. RNA was treated with DNase I 
(Invitrogen) for 15 minutes at room temperature. 1 µg of total RNA was reverse-
transcribed to cDNA with Superscript III First-Strand Synthesis SuperMix (Invitrogen) 
according to manufacturer’s instructions. cDNA was amplified using SYBR green and 
complementary reagents from Stratagene (La Jolla, CA) on a Stratagene MX3000. A 
standard, made from the cDNA of 25 different livers was run in each PCR for each 
target, and the quantification of each gene was normalized to mouse ribosomal protein 
RPL19 to control for RNA quality. 
Immunoblotting 
Insulin injected mice were sacrificed 10 minutes after injection. Flash frozen liver 
tissue was homogenized in Cell Lysis buffer (Sigma) containing a protease inhibitor and 
Phosphatase Inhibitor Cocktail 1 & 2 (Sigma). After the removal of the pellet, protein 
concentrations were determined colorimetrically using Bradford reagent (Bio-Rad). 30 
ug of protein from each lysate were loaded onto 10% precast NuPage mini-gels 
(Invitrogen). Gels were electrophoresed for 50 minutes at 200V. Proteins were 
transferred to PVDF membrane via wet electrophoresis for 1 hour at 60V. Membrane 
was blocked in 10% milk, washed, and incubated with primary antibody overnight at 4 
degrees C. Membrane was then washed and incubated in HRP-conjugated secondary 
antibody for 1 hour. Membrane was washed again, and incubated in luminal hrp-
substrate reagent (Bio-Rad) for 3 minutes, and exposed to film. Relative densities were 
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calculated using UltraQuant density calculation. Mouse monoclonal IRB (1:1000), rabbit 
polyclonal Ser473 Phospho-Akt  (1:1000), rabbit polyclonal Akt (1:1000), rabbit 
polyclonal B-Actin (1:2000) were purchased from Cell Signaling. Mouse monoclonal 
Srebp1 (1:100) was purchased from AbCam. 
Triglyceride Measurements 
50mg of flash frozen liver was homogenized in 2:1 chloroform methanol solution. 
The organic layer was separated and triglyceride content was measured colorimetrically 
with enzymatic Triglyceride kit (Sigma).  Serum measurements were performed as 
described above. 
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CHAPTER 3 
RESULTS 
 
Histological analysis of PAS stained liver sections showed different storage 
patterns in knockout and wildtype mice (Figure 1). WT mice had evenly spread 
glycogen stores. In FST288-only, DM, and FSTL3 KO mice, the glycogen was stored 
heterogeneously. Some portions of the liver had heavy stores of glycogen, while others 
had little to none. There was no obvious pattern as to where glycogen was preferentially 
stored. Upon glycogen extraction, it was clear that there were no significant differences 
in glycogen concentrations between any of the genotypes (Figure 3).  
PEPCK mRNA levels were not significantly higher in any of the knockout animals 
(Figure 4). Comparing DM to each background of WT shows ~2 fold increases in 
G6Pase mRNA levels (Figure 4). FSTL3 KO and 288-only mice have no significant 
increase, meaning that there is a compensatory effect in each of the single mutant mice, 
and ablation of both antagonists is necessary for the partial insulin resistant state. IRS1 
mRNA levels were about 1.5 fold higher in 288-only mice (Figure 4). It is interesting to 
note that DM mice had IRS1 levels equivalent to WT. It is also important to point out 
that there were no significant differences in IRS2 mRNA expression between any of the 
knockouts and their wildtype littermates (Figure 4). In FSTL3 KO and 288 only mice, 
GCK mRNA expression is slightly lower than their respective wildtypes (Figure 5), 
suggesting insulin resistance at this level, and potentially allowing glucose to reenter the 
bloodstream.   
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Insulin Receptor (IR) protein levels were significantly elevated in FST288-only 
mice (Figure 6). Akt is an important signaling molecule which mediates the metabolic 
actions of insulin 43. Akt is phosphorylated and activated downstream of IR and 
IRS1/IRS2. Akt protein levels were similar for FST288-only, DM, and WT (Figure 7). 
However, the pAkt/Akt levels of 288-only mice were significantly higher than FST WT. 
Sterol regulatory element binding protein 1c (SREBP1c) mRNA levels were not different 
between the genotypes (Figure 8).  
DM mice had PPARy mRNA expression at about 50% the level of their wt 
littermates, which was an unexpected result due to their steatotic livers (Figure 8). 
Lipase C and LDLR mRNA levels displayed similar patterns across the genotype panel, 
with 288-only mice exhibiting significantly higher expression levels for both genes 
(Figure 9). LDLR mRNA expression was ~5 fold higher in 288-only mice than FST WT. 
Given this information, it is possible that 288-only mice have increased LDL uptake in 
the liver, causing the steatosis.  
To determine if our mice had hepatic steatosis and to what extent, lipid extraction 
was performed and measured colorimetrically (Figure 10). FSTL3 KO, 288 only, and 
DM mice each had significantly higher triglyceride concentrations in their livers than WT 
mice. Next, to investigate hepatic triglyceride localization, livers were sectioned and 
stained with Hematoxylin and Eosin (Figure 11). All three mutant lines had a similar 
hexagonal pattern of TG accumulation. The liver sections show the TG accumulation 
primarily taking place at the perimeter of the hepatic lobule. This is where all the blood 
enters the liver, thus suggesting that excess fat is initially coming in through the blood. 
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To test this, a random serum triglyceride assay was performed. No significant 
differences were found between the genotypes (Figure 12). 
There were no detectable levels of myostatin mRNA in the liver (Figure 13). This 
could be due to levels being lower than the lower detection limits of a qPCR, or because 
myostatin is not made in the liver. Activin A is slightly elevated in FSTL3 KO, but slightly 
decreased in 288-only. Activin B expression was slightly decreased in DM mice.  
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CHAPTER 4 
 
DISCUSSION 
 
Hepatic glycogen is a good physiological marker for insulin sensitivity but it was 
rather difficult to quantify glycogen stores based on the histology. Apparent amounts 
differed drastically, even on the same liver section (Figure 2). It is possible that the 
triglyceride deposits may have shifted glycogen stores to peripheral areas, but we are 
not certain that this caused the pattern. The difficulty in analyzing heterogeneous tissue 
made it necessary to extract the glycogen out of the liver and quantify it colorimetrically. 
We purchased an enzymatic glycogen quantification kit from BioVision, but did not get 
reproducible results. A sulfuric acid-phenol quantification eventually proved to be the 
most reliable, with a consistent correlation coefficient of .999 for the standard curve. 
After quantification it was evident that glycogen concentrations in the knockout livers 
were not significantly different from wildtype. This was in part due to a large variability 
between each mouse in the fed state (Table 3).  
FSTL3 KO mice appeared to be insulin sensitive. They had normal levels of 
PEPCK, G6Pase, IRS1, and IRS2 mRNA expression. FST288-only mice appeared to 
be even more insulin sensitive than WT mice, expressing normal levels of PEPCK, 
G6Pase, and IRS2, but increased levels of IRS1 mRNA. FST288-only mice also had 
increased IR (insulin’s role in the downregulation of its own receptor is well 
established44 ) and pAkt/Akt protein levels. The DM mouse also appeared to be 
relatively insulin sensitive. They expressed normal levels of PEPCK, IRS1, and IRS2, 
but increased G6Pase, a sign of resistance. However, because IR and pAkt/Akt levels 
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were normal as well, DM livers still appear to be sensitive to insulin. The hepatic 
steatosis does not appear to originate with hepatic insulin resistance in the glucose 
regulatory pathway.  
An important point to realize is that the DM is a combination of both 
backgrounds. This can disguise certain results. For example, the FSTL3 background 
had ~2.5 fold higher IRS2 levels than the FST background. DM had levels consistent 
with the FST background. This shows that the FST background has a dominant effect 
on IRS2 gene transcription when combined with the FSTL3 background. Until further 
research is done, it is impossible to infer that DM had reduced IRS2 expression 
because of the comparison between DM and FSTL3 WT. 
SREBP1 protein measurements were difficult as the primary antibody was a 
mouse monoclonal and required an anti mouse HRP-conjugated secondary antibody. 
The anti mouse secondary antibody was detected in no primary loading controls at ~115 
kDa and 55 kDa sizes when gel was run in non-reducing conditions. When run in 
reducing conditions, the upper band disappeared, allowing for the detection of the 125 
kDa SREBP1 band.  
SREBPs are translated as precursors which are bound to the endoplasmic 
reticulum and the nuclear membrane. Upon activation, they are cleaved and able to 
enter the nucleas where they activate target gene transcription45. The mRNA expression 
of SREBP1c is increased in isolated rat hepatocytes exposed to insulin46, indicating that 
insulin should have an effect on transcription. SREBP1c mRNA levels were not elevated 
in any knockout mouse. However, SREBP1 protein levels were elevated in DM mice, 
meaning that lipogenesis likely had a role in the accumulation of hepatic TG in these 
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mice. FST288-only mice had normal SREBP1 protein levels, but increased LDLR and 
Lipase C mRNA expression. Thus, DM appear to have increased lipogenesis and 
FST288-only seem to have increased lipid uptake. 
The pattern of lipid deposits suggested that the cause for fatty liver begins with 
the incoming blood. Serum TG measurements indicated that at any given time, there 
was no increase. It is possible that the FSTL3 KO, 288-only, and DM mice have already 
accounted for the high peripheral release of lipids via hepatic storage. This would 
suggest that the liver is working as a buffer for serum TG levels. Visceral fat pad mass 
is reduced by 33% in each knockout but total body fat remains the same (FSTL3 KO, 
288-only), or increases (DM) (Unpublished data) indicating that there is some systemic 
alteration in lipid storage. It is unclear as to if there was initially a normal size fat pad 
and it just deteriorated, or if fat was never stored there. The former would be worth 
testing to determine if adipose insulin resistance caused the fatty liver. 
Myostatin primers worked well with muscle tissue, showing that the reagents 
were functional. The assay was repeated, and the lack of myostatin found in the liver 
was consistent. The differences in TGFβ ligand mRNA expression were minor. Activin A 
expression was not significantly different between knockout and wildtype mice. While 
there are differences, there is no evidence that these ligands directly act on liver tissue 
to change the metabolic profile of the mouse. All indications are that these ligands act 
peripherally to induce the metabolic phenotype. Even though activin B was reduced in 
DM mice, more research needs to be done to determine what effect it had on 
metabolism. In the future we will culture hepatocytes and treat with TGFβ ligands. 
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CONCLUSIONS 
Activin was discovered as a reproductive hormone with important functions as a 
stimulator of FSH secretion in the pituitary. Follistatin (FST), named for its inhibitory 
effect on FSH secretion, was found to be an extracellular antagonist of activin 
irreversibly binding to activin and preventing it from binding to its receptor. FST is 
produced in many tissues, with the highest expression being in ovarian tissue34.  Also 
part of the TGFβ family is myostatin, an inhibitor of muscle growth. FST also binds to 
myostatin, rendering it inactive. FSTL3 is similar in structure to FST, made in many 
tissues, but highest expression occurs in testes and placenta47. FSTL3 also blocks 
myostatin and activin activity in the same manner and like FST, is made to balance the 
potent effects of these TGFβ ligands.  Activin, although vital as a reproductive hormone, 
was also found to have metabolic functions. The FSTL3 knockout mouse was 
generated in order to better characterize activin effects on glucose homeostasis. 
Because the deletion of FSTL3 and/or FST increases the activity of both activin and 
myostatin, they both were considered in this study.   
Activin and myostatin appear to increase islet function in vivo. The higher serum 
insulin levels in response to similar serum glucose levels in the DM mouse are an 
indication that beta cells are overproducing. Further evidence for increased beta cell 
function is an increase in beta cell area and mass, and a higher level of pancreatic 
intracellular insulin content. The single knockouts also demonstrate increased insulin 
output, with DM > FSTL3 KO > 288 only > wildtype in regards to serum levels. 
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When peripheral tissues become resistant to insulin over time, beta cells detect 
more glucose in the blood supply prompting the secretion of more insulin. This is the 
beginning of the pathological condition, ultimately resulting in type 2 diabetes when beta 
cells cannot keep up with the demands of downregulated insulin response pathways. A 
good indication of insulin resistance is normal glucose levels complemented by high 
insulin levels. Higher insulin levels should promote lower glucose in the blood unless the 
response to insulin is attenuated somehow.  
DM mice had a reduced ability to clear high levels of glucose from the blood as 
well as reduced glucose clearance in response to insulin injection. FSTL3 KO mice had 
normal glucose, increased insulin, but did not turn out to be insulin resistant. In fact, 
FSTL3 KO had glucose tolerant and insulin sensitive results. Deleting only FSTL3 had a 
less potent effect on islet function, with peripheral tissues remaining sensitive to insulin. 
When both antagonists are removed, the effect is a giant increase in islet function and 
large quantities of insulin are secreted. It is possible that insulin is secreted in excess so 
dramatic that it causes peripheral tissues such as liver, muscle and/or adipose tissue to 
eventually decrease response. The activity of myostatin can be postulated to be higher 
in DM mice, not only because of the genetic background, but because of muscle data. 
The single deletion mice have no change in muscle mass, while the DM mouse has a 
40% reduction. Myostatin is known to be a potent muscle growth inhibitor48. The activity 
of activin is also likely to be higher due to the double mutant genotype. The phenotype 
also could be a secondary effect of the enhanced islets producing and secreting too 
much insulin. Their serum insulin levels were higher than WT and the single deletion 
mice, while their serum glucose was normal. This means that more insulin was 
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necessary to clear the same amount of glucose. It could also indicate that elevated 
insulin is the primary change and high insulin causes the necessity for the mice to eat 
more to balance glucose levels. To investigate further, a GTT was run. The GTT 
showed that blood glucose levels remained higher for longer after a glucose injection. 
An ITT was run to determine if their tissues were insulin sensitive or not. This showed 
that given the same amount of insulin, they cleared less glucose (unpublished data). All 
results in the DM mouse point to highly functioning islets with peripheral insulin 
resistance as a secondary effect. This shows that the ablation of the two main 
antagonists of myostatin and activin had a synergistic effect. 
Hepatic steatosis was found in all three genetically modified mice. This is a 
disorder heavily correlated with obesity, metabolic syndrome, and type 2 diabetes. 
Hepatic triglyceride accumulation in addition to the aforementioned insulin increase 
prompted the hypothesis that insulin resistance caused the steatotic livers. Hepatic 
specific insulin resistance was tested. FSTL3 KO mice appeared to be insulin sensitive. 
They had normal levels of PEPCK, G6Pase, IRS1, and IRS2 mRNA expression. 
FST288-only mice appeared to be more insulin sensitive than WT mice, expressing 
normal levels of PEPCK, G6Pase, and IRS2, but increased levels of IRS1 mRNA. 
FST288-only mice also had increased insulin receptor (insulin’s role in the 
downregulation of its own receptor is well established49 ) and pAkt/Akt protein levels.  
The DM mouse also appeared to be relatively insulin sensitive. They expressed normal 
levels of PEPCK, IRS1, and IRS2, but increased G6Pase, a sign of resistance. But 
because insulin receptor and pAkt/Akt levels were normal as well, DM mice still appear 
to be sensitive to insulin in their liver. Histological examination of glycogen was 
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inconclusive. In the knockout mice, it was difficult to determine whether there were 
higher levels of glycogen or not because of the heterogeneous deposits. Liver glycogen 
extractions showed no significant differences between the genotypes, including DM. 
Future research will include testing more mRNA and protein targets from the insulin 
signaling pathway to be certain of the hepatic insulin sensitivity. It will also include 
radiolabeling metabolites and following them as they are incorporated or broken down in 
the liver. Lastly, it will include testing adipose tissue for insulin resistance, because this 
is where fat should be stored; not the liver. It does not appear as though hepatic 
steatosis causes hepatic insulin resistance in these mice.   
Increased SREBP1 protein levels suggested that lipogenesis was the primary 
cause of fatty liver in the DM. The increased LDLR and Lipase C mRNA suggested that 
increased lipid uptake caused the fatty liver in FST288-only mice. The histology of the 
liver tissues of all three genotypes shows that fat accumulation occurred preferentially 
surrounding the areas where blood first enters the liver. It makes sense that as 
hepatocytes clear lipids from the blood, the reduction in blood lipids causes less to be 
taken up by the areas furthest from the entry point. To explain the DM, insulin directly 
activates SREBP1c mediated lipogenic action and insulin enters the liver from the same 
blood supply as lipids. Hepatocytes near the entry point would be affected the most. 
Thus, the cause for the hepatic steatosis was not confirmed. The interesting thing is that 
the mice present different models for fatty liver. None of them include hepatic insulin 
resistance as a cause, disagreeing with both popular beliefs: 1) Hepatic insulin 
resistance causes steatosis and 2) Steatosis causes hepatic insulin resistance.  
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Table 1. Comparison of Tissue Specific Insulin Receptor Knockout Mice 
 
 Circ glucose Circ Insulin Circ FFA, TG  
LIRKO High High Low  
MIRKO Normal Normal High  
FIRKO Normal Low Low  
Comparison of tissue-specific insulin receptor knockouts. 
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Table 2. Metabolic Comparison of FSTL3 KO, FST288-Only, DM Mice 
  
BW 
Visceral 
Fat Pad 
% Body 
Fat 
Muscle 
Mass 
Serum 
Glucose 
Serum 
Insulin 
 
GTT 
 
ITT 
FSTL3 
KO50 
Reduced Reduced Normal Normal Normal Slightly 
Increased 
Tolerant Sensitive 
FST288
-only 
Reduced Reduced Normal Normal Normal Normal Normal Normal 
DM Normal Reduced Increased Reduced Normal Increased Intolerant Insensitive 
 
Metabolic comparison of each of the genetically modified mice. Results relative to 
respective WT, or both WTs in the case of DM 
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Table 3. Variability of Liver Glycogen Concentrations Between Mice 
mg Glycogen/ g Liver Tissue in each mouse 
fstl3 wt fstl3 ko fst wt 288- 
only 
DM 
51.08 20.63 45.92 39.61 73.09 
17.54 38.99 43.05 50.95 42.57 
46.82 51.91 18.11 43.77 36.76 
32.20 40.53 8.21 11.51 34.51 
24.25 29.15 6.26 16.53 29.46 
12.38 13.63   18.60 30.44 
  28.94     30.26 
 
Hepatic glycogen concentrations for each sample, demonstrating the large 
variability. 
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Figure 1. Histologic Comparison of Liver Tissue Glycogen  
 
 
Fstl3 wt (A), fstl3 ko (B), fst wt (C), fst288-only (D), and dm (E) liver sections stained 
with Periodic acid-Schiff's stain. Glycogen stains magenta. (Magnification: x10)  
A B 
C D 
E 
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Figure 2. Intrahepatic Variability in Glycogen Storage 
A B 
Liver sections stained with Periodic acid-Schiff's stain. Micrographs taken from the 
same section of fstl3 ko tissue (A, B). Glycogen stains magenta. (Magnification: 
x10) 
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Figure 3. Biochemical Glycogen Analysis 
Hepatic Glycogen
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Hepatic glycogen concentrations measured via extraction and colorimetric 
quantification.  
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Figure 4. mRNA Expression of Insulin Response Components 
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mRNA expression levels of gluconeogenic genes PEPCK and G6P, and insulin 
receptor substrates 1 & 2 (IRS1, IRS2). Significance marked by * (p < .05) and ** 
(p < .01).  
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Figure 5. Gck mRNA expression 
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mRNA expression levels of glucokinase (GCK),  Significance marked by * (p < .05) 
and ** (p < .01).  
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Figure 6. Relative IRβ Protein Levels 
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Western blot; protein expression levels of IRβ normalized to β-Actin. Significance 
marked by * (p < .05) and ** (p < .01).  
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Figure 7. Relative pAkt Levels 
 
 
  
Western blot; phosphorylation levels of Akt. Significance marked by * (p < .05) and 
** (p < .01).  
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Figure 8. mRNA Expression of SREBP1 and PPARy 
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mRNA expression levels of SREBP1 and PPARγ. Significance marked by * (p < 
.05) and ** (p < .01).  
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Figure 9. mRNA Expression of Lipase C and LDLR 
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mRNA expression levels of Lipase C and LDLR. Significance marked by * (p < .05) 
and ** (p < .01).  
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Figure 10. Hepatic Triglyceride Concentrations 
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Liver triglyceride concentrations normalized to weight of tissue. Significance 
marked by * (p < .05), ** (p < .01), and *** (p < .001).  
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Figure 11. Fatty Liver Patterns 
 
Liver sections stained with H&E. Triglycerides appear as clear deposits. 
(Magnification: x10) 
 
37 
 
Figure 12. Serum Triglyceride Levels 
 
  
Serum triglyceride concentrations. Significance marked by * (p < .05), ** (p < .01), 
and *** (p < .001).  
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Figure 13. mRNA Expression Levels of TGFβ Ligands 
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mRNA expression levels of myostatin, activin bA, and activin bB. Significance 
marked by * (p < .05) and ** (p < .01).  
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Figure 14. Structure of Hepatic Lobule 
 
 
Diagram of functional unit of hepatic lobule (Cunningham, C.C., and Van Horn, C.G. Energy 
availability and alcohol-related liver pathology. Alcohol Research & Health27(4):281–299, 2003.) 
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